Valley Forge, PA, United States of America

Gregory Alcorn

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Trevena, Inc., Verrica Pharmaceuticals Inc.. Active years: 2016-2023.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2016-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gregory Alcorn: Innovator in Pharmaceutical Tools

Introduction

Gregory Alcorn is a notable inventor based in Valley Forge, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly with his innovative tools and compounds. With a total of 2 patents, Alcorn has established himself as a key figure in the industry.

Latest Patents

Among his latest patents is the "Ampule Crush Tool," which is designed to facilitate the crushing of ampules for easier access to their contents. Additionally, he has developed novel crystalline and amorphous forms of a β-arrestin effector. This patent provides processes for preparing these forms and outlines their various uses, showcasing Alcorn's commitment to advancing pharmaceutical technology.

Career Highlights

Throughout his career, Gregory Alcorn has worked with prominent companies such as Verrica Pharmaceuticals Inc. and Trevena, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking projects in the pharmaceutical sector.

Collaborations

Alcorn has collaborated with esteemed colleagues, including Eugene R. Scavola and Paul Daly. These partnerships have further enhanced his innovative capabilities and have led to the development of impactful pharmaceutical solutions.

Conclusion

Gregory Alcorn's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…